GlassScriptPhysician profile
Dominic King
NPI 1568771038
$3,532.60
in general payments reported to CMS, 2019-2025
30 companies · $2,245 in 2025
The $2,245 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $488 · 2023: $46.75 · 2024: $753 · 2025: $2,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,044.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $530.50 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $275.60 | 2024-2025 | Nuplazid |
| Janssen Pharmaceuticals, INC | $237.42 | 2022 | |
| Alexion Pharmaceuticals, INC. | $226.06 | 2025 | Ultomiris |
| Argenx US, INC. | $193.72 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Lilly USA, LLC | $193.59 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Octapharma USA, INC. | $192.96 | 2024-2025 | Panzyga |
| Mallinckrodt Hospital Products INC. | $153.86 | 2025 | Acthar |
| Lundbeck LLC | $152.47 | 2024-2025 | Rexulti, Vyepti |
| Axsome Therapeutics, INC. | $139.25 | 2025 | Symbravo |
| E.R. Squibb & Sons, L.L.C. | $129.58 | 2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $127.35 | 2024-2025 | |
| Neurelis, INC. | $119.21 | 2024-2025 | Valtoco |
| Merz Pharmaceuticals, LLC | $119.18 | 2025 | Inbrija, Xeomin |
| Biohaven Pharmaceutical Holding Company LTD. | $119.13 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $106.67 | 2024-2025 | Fintepla, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $92.45 | 2024-2025 | Austedo Xr, Ajovy |
| Amneal Pharmaceuticals LLC | $67.72 | 2024-2025 | Rytary, Crexont, Brekiya |
| Sk Life Science, INC. | $56.58 | 2025 | |
| Janssen Biotech, INC. | $55.65 | 2025 | |
| Springworks Therapeutics, INC. | $43.35 | 2025 | Gomekli |
| Ani Pharmaceuticals, INC. | $35.42 | 2024 | Purified Cortrophin Gel |
| Impel Pharmaceuticals LLC | $25.71 | 2025 | Trudhesa |
| C2n Diagnostics, LLC | $24.80 | 2025 | Precivityad2 |
| Genzyme Corporation | $23.38 | 2025 | |
| Genentech USA, INC. | $21.69 | 2025 | Ocrevus Zunovo |
| Csl Behring | $21.34 | 2025 | Hizentra |
| Vanda Pharmaceuticals INC. | $19.79 | 2025 | Ponvory |
| Biogen, INC. | $17.91 | 2024 | Vumerity |
| Aucta Pharmaceuticals, INC. | $10.26 | 2024 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dominic King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.